Retinal vein occlusion often requires ongoing treatment over years, not months, but long-term outcome data from real-world practice has historically been scarce. Dr Adrian Hunt’s co-authored study addressed this gap by tracking treatment-naïve patients with central retinal vein occlusion (CRVO) from their first anti-VEGF injection through three years of care, using the Fight Retinal Blindness! registry.
The study was published in Ophthalmology Retina in 2023. Earlier results were presented at the RANZCO 2022 annual congress, where the abstract was selected as an Australian Vision Research (AVR) Recommended Abstract — a designation highlighting research of particular value to the Australian vision research community.
The published paper was subsequently featured by MacularNEWS (Save Sight Institute) and NZ Optics, making the findings accessible to optometrists and eye-care professionals across Australasia.
What this means for patients: Patients starting injection treatment for CRVO want to know what to expect not just in the first few months, but over the years ahead — how vision typically responds, how many injections to expect, and what long-term outcomes look like in routine practice rather than under clinical trial conditions. This research provides that picture.